Loading...
On the basis of mounting evidence from studies of hormone replacement therapy (HRT), the American Heart Association (AHA) has issued summary recommendations on HRT and cardiovascular disease (CVD). The general principle underlying the recommendations is that decisions about HRT should focus on noncardiovascular benefits and risks.
HRT should not be initiated for secondary prevention. For women with CVD who are currently receiving long-term HRT, decisions about continuing or ceasing therapy should be based on assessment of noncoronary risks and benefits. When current HRT users suffer adverse cardiovascular events, consider stopping HRT altogether or consider anticoagulation to minimize thromboembolic events in the setting of immobilization.
Al…